LUC-201
Undisclosed (likely aging-related disorders)
PreclinicalActive
Key Facts
Indication
Undisclosed (likely aging-related disorders)
Phase
Preclinical
Status
Active
Company
About Lucina Biotherapeutics
Lucina Biotherapeutics is a preclinical-stage biotech founded in 2022, pioneering a novel approach to treating aging-related diseases by restoring declining levels of Very Long Chain Poly-Unsaturated Fatty Acids (VLC-PUFAs). The company's core asset is the PUFActive platform, which includes both intravitreal and oral drug delivery modalities, with its lead program LUC-101 for dry AMD in IND-enabling studies. Led by an experienced team with backgrounds in ophthalmology, drug development, and synthetic biology, Lucina is positioned to address a significant unmet need in large markets like dry AMD, where no approved therapies exist.
View full company profile